New York, USA, May 19, 2026 (GLOBE NEWSWIRE) -- Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight ...
Future Cardiol. 2013;9(3):335-349. The pivotal trial that established sildenafil as a treatment for WHO Group 1 PH was the SUPER trial. [102] SUPER enrolled WHO functional class II and III PAH ...
A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...
Pulmonary arterial hypertension, a relentless and often fatal disease in which the blood vessels of the lungs progressively ...
Molecular profiles may help create more effective individualized treatment for pulmonary arterial hypertension, researchers ...
Indiana University School of Medicine researchers at the school's South Bend regional campus, in collaboration with colleagues at the University of Notre Dame, have identified a new therapeutic target ...
Researchers estimate that about 1% of the world’s population lives with pulmonary hypertension — a condition causing high blood pressure in the blood vessels in the lungs. There is currently no cure ...
Newswise — Discoveries in the lab of Youyang Zhao, PhD, at Stanley Manne Children’s Research Institute at Lurie Children’s, hold promise of new treatments for patients suffering from pulmonary ...
In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...
WHAT IS PULMONARY ARTERIAL HYPERTENSION (PAH)? Pulmonary Arterial Hypertension (PAH) is a severe and progressive form of pulmonary hypertension, characterised by elevated blood pressure in the ...
High blood pressure can indirectly cause shortness of breath by forcing the heart to work harder, which may lead to cardiovascular issues. Pulmonary hypertension, a specific type of high blood ...